Nanoviricides, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersShelton, CT
SAM.gov UEICT29G7EA5ZU1
NanoViricides develops broad-spectrum nanoviricides, which are viral therapeutics designed to bind to and destroy virus particles. The company is developing nanoviricide candidates including NV-387 for RSV, COVID-19, influenza, bird flu, smallpox and monkeypox; NV-HHV-1 for shingles and herpes family viruses; and other nanoviricides for dengue, rabies, and Ebola/Marburg. The company serves the pharmaceutical and viral disease treatment industry.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Nanoviricides, INC. | Shelton | CT | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.